Comparative Pharmacology
Head-to-head clinical analysis: AYGESTIN versus NORGESTIMATE ETHINYL ESTRADIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AYGESTIN versus NORGESTIMATE ETHINYL ESTRADIOL.
AYGESTIN vs NORGESTIMATE; ETHINYL ESTRADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial changes by binding to progesterone receptors.
Combination oral contraceptive containing norgestimate (a progestin) and ethinyl estradiol (an estrogen). The primary mechanism is suppression of gonadotropins (FSH and LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, preventing ovulation. Additional effects include thickening cervical mucus (inhibiting sperm penetration) and altering endometrial receptivity.
5 mg orally once daily for secondary amenorrhea; 5 mg orally once daily from day 5 to day 25 of menstrual cycle for abnormal uterine bleeding.
Oral, one tablet daily at the same time for 21 days, followed by 7 placebo tablets.
None Documented
None Documented
Terminal half-life 5-12 hours; clinical context: requires twice-daily dosing for consistent serum levels.
Norgestimate: terminal half-life of norelgestromin (active metabolite) is 27.6 ± 7.8 hours; ethinyl estradiol: terminal half-life is 17.5 ± 6.3 hours. Steady state achieved within 14 days.
Approximately 50-80% renal as metabolites, 10-20% fecal; less than 1% unchanged.
Norgestimate metabolites are primarily excreted via urine (60-80%) and feces (35-49%) as glucuronide and sulfate conjugates; ethinyl estradiol is excreted in urine (40%) and feces (60%) as conjugates.
Category C
Category D/X
Progestin
Progestin + Estrogen